Survival determinants in lung transplant patients with chronic allograft dysfunction

Transplantation

Volumn 92, Issue 6, 2011, Pages 703-708

  Verleden, Geert M ^a   Vos, Robin ^a   Verleden, Stijn E ^b   De Wever, Walter ^a   De Vleeschauwer, Stéphanie I ^b   Willems Widyastuti, Anna ^b   Scheers, Hans ^b   Dupont, Lieven J ^a   Van Raemdonck, Dirk E ^a   Vanaudenaerde, Bart M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

BOS; CLAD; Lung transplantation; Phenotyping; RAS

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; BRONCHIECTASIS; CHRONIC LUNG ALLOGRAFT DYSFUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEMANGIOENDOTHELIOMA; HUMAN; LUNG DISEASE; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG INFILTRATE; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHILIC REVERSIBLE ALLOGRAFT DYSFUNCTION; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; FEMALE; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 81155162615     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822bf790     Document Type: Article

References (25)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentyseventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010; 29: 1104.
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
3. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832.
4. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, et al. Follicular bronchiolitis: A rare cause of bronchiolitis obliterans syndrome after lung transplantation: A case report. Am J Transplant 2009; 9: 644.
5. McManus TE, Milne DG, Whyte KF, et al. Exudative bronchiolitis after lung transplantation. J Heart Lung Transplant 2008; 27: 276.
6. Pakhale SS, Hadjiliadis D, Howell DN, et al. Upper lobe fibrosis: A novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 2005; 24: 1260.
7. Woodrow JP, Shlobin OA, Barnett SD, et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29: 1159.
8. Sato M, Waddell TK, Wagnetz D, et al. Restrictive allograft syndrome (RAS): A novel form of chronic allograft dysfunction. J Heart Lung Transplant 2011; 30: 735.
9. Glanville AR. Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med 2010; 31: 208.
10. Verleden SE, Vos R, Mertens M, et al. Heterogeneity of chronic lung allograft dysfunction: Insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011; 30: 667.
11. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomized placebocontrolled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2011; 37: 164.
12. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948.
13. Martinu T, Howell DN, Davis RD, et al. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 2006; 129: 1016.
14. Burton CM, Iversen M, Carlsen J, et al. Interstitial inflammatory lesions of the pulmonary allograft: A retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008; 86: 811.
15. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36.
16. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer? J Heart Lung Transplant 2010; 29: 1358.
17. Riise GC, Andersson BA, Kjellström C, et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 1999; 14: 1123.
18. Devouassoux G, Drouet C, Pin I, et al. Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol 2002; 10: 303.
19. Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009; 28: 468.
20. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566.
21. Finlen Copeland CA, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182: 784.
22. Lama VN, Murray S, Lonigro RJ, et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007; 175: 1192.
23. Brugière O, Pessione F, Thabut G, et al. Bronchiolitis obliterans syndrome after single-lung transplantation: Impact of time to onset on functional pattern and survival. Chest 2002; 121: 1883.
24. Jackson CH, Sharples LD, McNeil K, et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): Are they different entities? J Heart Lung Transplant 2002; 21: 658.
25. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107.